Select Page

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Eidos Therapeutics, Inc. (NASDAQ: EIDX) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with BridgeBio Pharma, Inc. (NASDAQ: BBIO).